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Abstract
Objective: One in three women living with HIV (WLHIV) in the UK is aged 45–56, and therefore of potentially
menopausal age. Little is known about the management of menopause in WLHIV in primary care. We aim to describe
current knowledge and practice in the management of menopause in WLWH among primary care practitioners (PCPs).
Methods: A questionnaire-based study of 88 PCPs attending two sexual and reproductive health conferences.
Results: Almost all respondents (n¼ 87, 99%) routinely managed women with menopause-related symptoms; however,
only 18 (20%) reported having managed menopause in WLHIV. Over 95% (n¼ 85) reported being confident in managing
menopause in general, whereas less than half (n¼ 40) reported confidence in managing menopause in WLHIV
(p< 0.001). The majority of respondents (n¼ 84) felt that menopause should be routinely managed in primary care,
whereas just over half thought that menopause in WLHIV should be managed in primary care (n¼ 50, p< 0.001). Almost
all respondents (n¼ 85) reported concerns about managing menopause in WLHIV.
Conclusion: PCPs reported limited experience of and low levels of confidence in managing menopause-related symp-
toms in WLHIV. Nearly all PCPs had concerns about managing menopause-related symptoms in WLHIV, many stating
that this should be managed outside primary care. Development of national guidance and specialised training, coupled
with good liaison between HIV services and PCPs, may improve confidence in this area.
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Introduction
The widespread availability of antiretroviral therapy
(ART) has transformed HIV from a life-limiting condi-
tion to one which is chronic with normal life expectancy
for many. HIV care today predominantly involves
managing co-morbidities, drug interactions and the
eﬀects of HIV on ageing. Consequently, the impact of
HIV on ageing has emerged as an important area of
research interest, with attention focused on cardiometa-
bolic disease and neurocognitive impairment.
Increasing numbers of older women are living
with HIV, with one in three women living with HIV
(WLHIV) attending for HIV care in the UK in 2014
estimated to be aged 45–56 years,1 and therefore of
potentially menopausal age. We anticipate that clin-
icians will be likely to see increasing numbers of
WLHIV with menopause-related symptoms. However,
little is known about the menopause in this population.
Menopausal symptoms are common in the general
population and experienced by 85% of women.2 They
persist for a median duration of seven years3 and have
been shown to adversely aﬀect quality of life and role-
functioning in work and personal relationships.4,5
Management options for menopausal symptoms
include (but are not limited to) lifestyle modiﬁcation,
cognitive behavioural therapy and hormone replace-
ment therapy (HRT). Recently published UK guidance
by the National Institute for Health and Care
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Excellence (NICE) recommends that HRT be discussed
and oﬀered to women with menopausal symptoms.6
A recently published review paper concluded that
WLHIV are likely to experience menopause earlier
than their HIV-negative counterparts and that they
may experience more symptoms.1 Furthermore, data
suggest that symptoms of menopause are often misat-
tributed by both patients and clinicians to HIV-related
illness or side eﬀects of ART.7 Finally, WLHIV are at
risk of poor mental health and social marginalisation,8
which may add further complexity to their menopause
experience.
In the UK, menopause is currently mainly managed
within primary care. However, healthcare providers
within primary care may see small numbers of people
living with HIV, and are therefore likely to have limited
experience of managing comorbidities and drug
interactions in this population. In contrast, healthcare
providers within HIV specialist services may lack
experience of managing menopause. It is therefore
unsurprising that a recent qualitative study has found
that WLHIV ﬁnd themselves caught between primary
and tertiary care services, with their menopausal symp-
toms not being addressed.9
Although integrated clinics combining HIV and
menopause care are a welcome service development
for this patient group, provision of this type of service
is extremely limited in the UK. Specialist gynaecology-
led menopause services largely see patients who have
contraindications to HRT, who have symptoms that do
not respond to treatment, or are experiencing signiﬁ-
cant side eﬀects from treatment.
There is a paucity of data on how menopause
in WLHIV is managed within primary care. In this
paper, we describe, for the ﬁrst time in the UK, know-
ledge and practice regarding management of the meno-
pause in WLHIV amongst primary healthcare providers.
Methods
In October–November 2015, we conducted a
questionnaire-based study of primary care practitioners
(PCPs) with a special interest in reproductive and post-
reproductive health. The questionnaire covered three
key areas: respondent demographics; management of
menopausal symptoms in HIV-negative women and
management of menopausal symptoms in WLHIV.
The questionnaire was piloted amongst a small group
of general practitioners (GPs) prior to being adminis-
tered to respondents to inform the conduct of the
study. The outcome of the pilot resulted in shortening
of the survey and changes to the wording of a few ques-
tions. We subsequently conducted a further pilot study
at the annual Royal College of General Practitioners
conference in 2015; unfortunately, we achieved a 1%
response rate. Following this low response rate, we
decided to target PCPs attending two sexual and repro-
ductive health meetings aimed at healthcare providers
with an interest in this area.
Self-completed paper questionnaires were distribu-
ted to PCPs attending two sexual and reproductive
health meetings in London. Data were entered into
Excel and analysed using Stata 14.0 (StataCorp. 2015.
Stata Statistical Software: Release 14. College Station,
TX: StataCorp LP).
Results
We administered a total of 500 questionnaires, with a
response rate of 19% (95 out of 500). Seven question-
naires were excluded because they were incomplete or
completed by health professionals not currently work-
ing in primary care. This analysis is therefore based on
data from 88 respondents.
Demographics of respondents
The median age of respondents was 47 years (interquar-
tile range: 34–61 years) and the median year of qualiﬁ-
cation was 1996 (Table 1). Most respondents were
female (n¼ 82, 93%) and working as GPs (n¼ 81,
92%). Nearly 90% of respondents worked in medium–
large sized practices. Approximately half worked in
practices in England (but outside London) and 39%
(n¼ 33) were based in London.
Consultations
Almost all respondents reported that they managed
menopause in their primary care service (n¼ 87,
99%), with 75% seeing women for menopause-related
consultations ‘often’ (Table 2). Two-thirds (n¼ 57)
reported having seen WLHIV for general consultations
in their practice. A signiﬁcantly higher proportion of
respondents from London reported having seen
WLHIV for general consultations compared with
respondents from other geographical regions (79% vs.
60%, p< 0.05). One-ﬁfth (n¼ 18) reported having man-
aged menopause-related symptoms in WLHIV; 60% of
these respondents were based in London.
Managing menopause
Almost all respondents (n¼ 85, 97%) reported conﬁ-
dence in managing menopause in general, whereas
less than half reported being conﬁdent in managing
menopause in WLHIV (47%, p< 0.001). There was
no association between conﬁdence in managing meno-
pause in HIV and respondent gender, age, clinical role,
practice size or region (all p> 0.05).
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Nearly all respondents thought that menopause in
HIV-negative women should be managed in primary
care (n¼ 84, 96%). However, only half (n¼ 40) thought
that menopause in WLHIV should be managed in pri-
mary care. Instead, just over a ﬁfth (22%) thought
WLHIV with menopausal symptoms should be mana-
ged in specialist menopause clinics, with a further 24%
believing that menopause-related care should be pro-
vided HIV specialist teams.
Concerns about managing menopause in WLHIV
Almost all respondents (n¼ 85, 99%) expressed con-
cerns about managing menopause in WLHIV (based
on a clinical scenario). This contrasts with 81%
(n¼ 71) who stated that they had concerns about mana-
ging menopause in general (p< 0.001). Key concerns
identiﬁed by respondents (Figure 1), included potential
drug–drug interactions (n¼ 68, 79%) and fear of missing
an HIV-related illness (n¼ 44, 51%). Almost half
reported having the same concerns as they would have
when managing menopause in women without HIV.
There was a particular emphasis in the free text sec-
tion of the questionnaire on a lack of knowledge and
experience in this area and the likely underuse of HRT
in WLHIV.
One-ﬁfth of respondents did not identify any further
training needs, mainly because they did not routinely
see WLHIV in their clinical practice. However, three-
quarters (n¼ 68) stated that they would beneﬁt from
further training in menopause and HIV.
Discussion
This small questionnaire study reveals that less than
half of PCPs surveyed lacked conﬁdence in managing
menopause in WLHIV, in contrast to high levels of
reported conﬁdence in managing menopause in
women without HIV. This is of particular concern for
PCPs working in London, who are more likely to see
WLHIV because of the higher prevalence of diagnosed
HIV.10
The management of menopause in WLHIV may
sometimes (but not always) involve considering alter-
native HIV-related diagnoses and potential drug–
drug interactions. Both were identiﬁed as key concerns
by our respondents. Similar concerns have been
found in previous studies among GPs exploring barriers
to managing comorbidities in people living with
HIV.11,12
A signiﬁcant proportion of respondents believed
that menopause in WLHIV should be managed in
tertiary services (either within specialist menopause
clinics or by HIV specialist teams), reﬂecting a lack of
conﬁdence and knowledge in this area. Three-quarters
Table 1. Participant and practice characteristics.
Demographics
Number of
participants, n (%)
Professional role
General practitioner 81 (92)
Practice nurse 3 (3)
Other 4 (5)
Age
Median 47 years
(IQR: 34–61 years)
Gender
Female 82 (93)
Male 6 (7)
Year of qualifying
<1990 28 (32)
1990–1999 24 (28)
2000 35 (40)
Practice size
Small: <5000 patients 9 (10)
Medium: 5000–10,000 patients 36 (42)
Large: >10,000 patients 39 (46)
Practice region
London 33 (39)
England (outside London) 45 (54)
Wales, Northern Ireland or Scotland 4 (5)
Other 2 (2)
IQR: interquartile range.
Table 2. Respondent experience of managing women with and
without HIV.
Number of
participants, n (%)
How often do you see women with
menopause-related issues?
Often 66 (75)
Occasionally 21 (24)
Never 1 (1)
How often do you see women living with
HIV for general consultations?
Often 2 (2)
Occasionally 55 (63)
Never 31 (35)
How often do you see women living with
HIV for menopause-related issues?
Often 0
Occasionally 18 (20)
Never 70 (80)
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of respondents stated they would beneﬁt from fur-
ther training on menopause speciﬁcally in the context
of HIV.
It is reassuring that over half of our respondents
believed that menopausal symptoms in WLHIV
should be managed in primary care. It is likely that
primary healthcare providers are best placed to
manage menopause in this group given their experience
in managing menopause more generally and their
ability to integrate menopause care with broader pre-
ventative healthcare measures as women get older.
There is no reason why WLHIV should necessarily be
managed diﬀerently to women without HIV, or indeed
women with other chronic medical conditions, by virtue
of their HIV status alone. Where concerns arise regard-
ing drug interactions, alternative diagnoses or psycho-
social complexity, close liaison and joint management
with HIV specialists is essential to support PCPs to
deliver the best care for these patients.
Providing training will be key in developing conﬁdence
and competence amongst primary care practitioners to
manage WLHIV with menopausal symptoms. This
could be in the form of specialist training for those mana-
ging menopause by means of e-learning, or lectures
within existing training packages.
As identiﬁed by some of participants, the develop-
ment of specialist guidance on managing the meno-
pause in WLHIV would be valuable. We therefore
welcome the inclusion of a section on menopause in
the forthcoming British Association of Sexual Health
and HIV guidelines on the reproductive healthcare of
people living with HIV. This will help build consensus
on the management of menopause in this population.
Where there are existing specialist menopause clinics
within tertiary care, referral pathways should be encour-
aged for complex HIV-positive patients who cannot be
managed in primary care. However, should menopause
care for this group be restricted solely to tertiary care, it is
unlikely that the majority of women will receive the care
they require. Instead, it is imperative to foster close liai-
son between HIV services and primary care, so that PCPs
feel supported in managing menopause in WLHIV.
Limitations
This was a small study with a low response rate which
limits the generalisability of our results. We recruited
practitioners who were attending sexual and reproduct-
ive health meetings and who therefore had a particular
interest in reproductive and post-reproductive health.
This is a group of predominantly middle-aged women
who were regularly managing menopause in their cur-
rent practice and are therefore likely to be particularly
knowledgeable in this area. Two-ﬁfths of participants
were based in London; this will introduce bias as par-
ticipants practicing in London (where there is a higher
prevalence of HIV) would be more likely to see
WLHIV for general and menopause-related consult-
ations. Their experiences and knowledge around HIV
and menopause are likely to diﬀer from those practicing
in areas of lower HIV prevalence. Consequently, these
ﬁndings represent ‘a best-case scenario’ of primary care
practitioners’ knowledge of managing menopause in
WLHIV and may not reﬂect the wider population of
PCPs (whose knowledge and conﬁdence may be even
more limited).
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Figure 1. Concerns about managing menopause in women living with HIV.
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Due to the nature of this survey, we were limited in
our scope to interrogate participants’ concerns regard-
ing the management of menopause in WLHIV in detail.
Conclusions
To the best of our knowledge, this is the ﬁrst study in
the UK (and one of the ﬁrst internationally) to explore
the management of the menopause in WLHIV amongst
PCPs. There is a growing population of WLHIV reach-
ing menopausal age and therefore increasing clinical
need. Despite the limitations introduced by sampling,
sample size and respondent characteristics, our data
provide some useful insights. We found low conﬁdence
amongst PCPs in managing menopause in WLHIV,
despite half of our participants indicating primary
care as the most appropriate setting for the manage-
ment of menopause in this population. Developing
training and specialist guidance on HIV and meno-
pause, and formulating clear care pathways for
onward tertiary referral when needed, is likely to be
key in developing conﬁdence and knowledge in this
emergent area, supporting PCPs to deliver high-quality
care to WLHIV transitioning through the menopause.
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